Stuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026
A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.
Stuart Curbishley, Chief Development & Manufacturing Officer, adthera bio | Onyx Live | Advanced Therapies 2026
Stuart Curbishley on how adthera bio is tackling the biggest bottleneck in cell and gene therapy: getting therapies manufactured at scale.
Miguel Forte, President, International Society for Cell & Gene Therapy | Onyx Live | Advanced Therapies 2026
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.